- Home
- RDCM vs CTNM Comparison
RDCM vs CTNM Comparison
Compare RDCM & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDCM | CTNM |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 550.7M |
| IPO Year | 1999 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RDCM | CTNM |
|---|---|---|
| Price | $10.23 | $7.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $14.00 | ★ $22.14 |
| AVG Volume (30 Days) | 55.4K | ★ 1.2M |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.56 | N/A |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.40 | $7.72 |
| 52 Week High | $16.74 | $17.79 |
Technical Indicators
Market Signals| Indicator | RDCM | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 24.11 |
| Support Level | $10.07 | N/A |
| Resistance Level | $10.49 | $14.27 |
| Average True Range (ATR) | 0.22 | 1.19 |
| MACD | 0.00 | -0.48 |
| Stochastic Oscillator | 61.40 | 2.12 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.